[Fixed combination of inhalant steroids and long-acting beta(2) agonists].
Petermann
W
W
Medizinische Klinik, Brüderkrankenhaus St. Josef Paderborn. w.petermann@bk-paderborn-de
Mutschler
E
E
D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000420:Albuterol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D019819:Budesonide / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D015536:Down-Regulation / Q000187:drug effects; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage*; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D006801:Humans; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004983:Ethanolamines; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol; D000068759:Formoterol Fumarate